Lexicon Genetics changes name and refocuses business
Refocusing Business to Achieve Goal of Advancing Ten Drug Candidates into Human Clinical Trials by 2010
Lexicon Genetics Incorporated announced that it is changing its name to Lexicon Pharmaceuticals, Inc. to reflect that it is focusing its operations on drug discovery and development activities related to its 10to10 Program. The 10to10 Program is an ongoing company initiative with the goal of advancing ten drug candidates into human clinical trials by 2010. Lexicon's planned name change will be submitted for shareholder approval at its upcoming annual shareholder meeting.
Lexicon expects the 10to10 clinical development programs to result from its internal drug discovery efforts as well as from efforts with collaborators. Lexicon has two proprietary compounds in human clinical trials and anticipates filing investigational new drug applications for two additional compounds in 2007.
Other news from the department business & finance

Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.